Preliminary results suggest potential to support extended preservation time and donor heart utilization TORONTO–(BUSINESS WIRE)–XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified […]